30. The fusion protein to transport the brain effector entity across the blood brain barrier of claims 28 or 29, wherein the sFab directed to the blood brain barrier receptor is a sFab directed to the transferrin receptor, preferably a scFab recognizing an epitope in the transferrin receptor comprised within the amino acid sequence of Seq. Id. No. 14, 15 or 16.

31. The fusion protein to transport the brain effector entity across the blood brain barrier of claims 28 to 30, wherein the linker is peptide linker.

32. The fusion protein of claims 28 to 31, wherein the CH2-CH3 Ig entity is a CH2-CH3 IgG entity.

33. An isolated nucleic acid encoding the fusion protein of claims 28 to 32.

34. A host cell comprising the nucleic acid of claim 33.

35. A conjugate comprising a fusion protein to transport a brain effector entity across the blood brain barrier of claims 28 to 32 and a brain effector entity coupled to a N-terminal end of the CH2-CH3 Ig entity of the fusion protein by a linker.

36. The conjugate of claim 35, wherein the brain effector entity is selected from the group consisting of proteins, polypeptides and peptides.

37. The conjugate of claim 36, wherein a C-terminal end of the effector entity is coupled to the N-terminal end of the CH2-CH3 Ig entity by the linker.

38. A pharmaceutical formulation comprising the conjugate of claims 35 to 37 and a pharmaceutical carrier.

39. The conjugate of claim 35 to 37 for use as medicament.

40. Use of the conjugate of claims 35 to 37 in the manufacture of a medicament.

41. The use of claim 40, wherein the medicament is for the treatment of a neurodegenerative disorder, preferably Alzheimer's disease.

~~42. The invention as described herein before.~~